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1744clinician expertise, but we were unable to address
these issues in the current study.
In conclusion, we agree with Dr. Carr that most
physicians work hard to improve the care of their
patients and make good clinical decisions. How-
ever, as seen in many aspects of medicine, the use of
more expensive treatment modalities in the absence
of evidence to support their use is often associated
with variation and should be examined. In the case
of PVI, we concluded that changes to the OPPS,
although designed to improve efﬁciency and reduce
costs, likely contributed to more use of atherectomy
and neutralization of cost savings to the Medicare
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Multivessel Primary PCI
The Debate ContinuesThe paper by Gershlick et al. (1) supports the concept
of coronary angioplasty of nonculprit lesions (NCLs)
at index admission based on visual assessment of
severity in patients presenting for primary percuta-
neous coronary intervention (P-PCI). This issue has
been debated for years.
It has been shown that only one-third of NCL-
associated events occur from angiographically signi-
ﬁcant NCLs, whereas two-thirds of events occur fromangiographically insigniﬁcant lesions or from normal
or nearly normal segments (2). NCL characteristics
associated with major adverse cardiac event were a
plaque burden of $70% and a minimal luminal area
of #4 mm2 and not angiographic severity alone.
Thus, ﬁxing all the visually signiﬁcant lesions at the
time of P-PCI may not be a prudent idea. Estimation of
NCL severity by fractional ﬂow reserve during the
acute phase of myocardial infarction (MI) is reliable
and may aid in intervening in ischemia-producing
lesions only (3).
Overestimation of NCL severity during acute MI is
well known (4), andmany of the apparently signiﬁcant
NCLs during the acute phase of MI may not require PCI
in follow-up therapy. It may be related to vascular
remodeling and healing of some of the NCLs over time.
Plaque passivation by medical therapy may diminish
slow ﬂow or no-reﬂow during PCI of NCLs, improve
myocardial perfusion, and favorably affect prognosis.
It would be interesting to know the lesion
morphology in 2 groups of this trial. Lesion charac-
teristics and anatomical variables may confound the
outcomes if not equally balanced in 2 groups. Stent
thrombosis after P-PCI is another cause for concern.
Acute vessel closure and stent thrombosis are re-
ported to be more frequent after multivessel PCI in a
highly prothrombotic environment of ST-segment
elevation MI with activated platelets and poor gas-
trointestinal absorption of clopidogrel.
With the current state of knowledge on this subject,
caution is required to translate these results into
clinical practice, when we see the articles suggesting
deferred stenting strategy for ST-segment elevation
MI (5) on one side of the spectrum and multivessel
stenting during P-PCI on the other.*Sanjeev K. Agarwal, MD, DM, CBCCT
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The Debate ContinuesThe CvLPRIT (Complete versus Lesion-only Primary
PCI Trial) (1) investigators welcome the comments of
Dr. Agarwal. CvLPRIT was designed as a pragmatic
trial of treatment strategies in real-world patients:
randomization was carried out therefore on the basis
of angiographic assessment of noninfarct-related ar-
tery (N-IRA) lesion severity as this remains the most
common method for N-IRA lesion assessment during
primary percutaneous coronary intervention (P-PCI).
Pressure-wire assessment is less commonly per-
formed during P-PCI than during catheterization for
stable patients or those presenting with acute coro-
nary syndromes (ACS)/non–ST-segment elevation
myocardial infarction (NSTEMI). We recognize, how-
ever, the growing evidence regarding the limitation
of angiography in deﬁning lesions responsible for
ischemia (2).
Although putative mechanisms of widespread
coronary inﬂammation causing plaque instability
are recognized, potentially predisposing to ischemic
events in N-IRA lesions of even modest severity (for
example, those exhibiting thin-cap ﬁbroatheroma),
this hypothesis remains unproven. No data have yet
emerged suggesting interventionists should make a
paradigm shift from the strategy of ischemia
reduction to that of “plaque stabilization” of non-
ischemic bystander lesions during the post-STEMI
period (3).
Baseline angiographic characteristics of the 2
treatment groups in CvLPRIT were not signiﬁ-
cantly different (1). Despite having three times as
many stents implanted, the complete revasculari-
zation group did not have any increase in stent
thrombosis.
However, CvLPRIT was not designed to answer all
the questions regarding multivessel disease in pa-
tients undergoing P-PCI, only the one that faced us at
the time: “if faced in the catheterization laboratory
with such a patient, should one even consider com-
plete revascularization?” Design of a single deﬁnitivetrial to resolve the unanswered questions surround-
ing STEMI management remains challenging. The
consistency of both CvLPRIT and PRAMI (Preventive
Angioplasty in Myocardial Infarction) in demon-
strating large treatment effects in favor of complete
revascularization undoubtedly inﬂuenced the Amer-
ican College of Cardiology “Choosing Wisely” advice,
which had been against PCI of N-IRA lesions
following STEMI (4).
There remain several unanswered questions. The
need for a single deﬁnitive large study examining
the effect of complete revascularization upon hard
endpoints, comparing complete revascularization
during the index admission with revascularization
at an interval of 6 to 8 weeks and determining the
utility of fractional ﬂow reserve (FFR) guidance, is
urgent.
The CvLPRIT/PRAMI investigators are currently
seeking funding for a large multicenter randomized
study, the PRIMETIME (PRIMary-PCI&N-IRA Evalu-
ation Trial- In-patient v Medical v dEferred str-
ategies) trial. This trial will recruit 2,750 patients
and randomize them to both a treatment strategy
(culprit-only, in-patient complete or staged out-
patient complete at 6 to 8 weeks) and to an
angiographic or FFR-driven N-IRA assessment to
determine outcome in terms of hard clinical end-
points. Expanded mechanistic information will be
available from a large cardiac magnetic resonance
substudy. Other large ongoing trials such as the
COMPLETE trial (Complete vs Culprit-only Revas-
cularization to Treat Multi-vessel Disease After
Primary PCI for STEMI) are also likely to provide
important information in this contentious and un-
resolved area.Damian J. Kelly, MB, ChB, MD
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